IFNAR1 and melanoma: The efficacy of IR was abolished in B16F10 melanoma and EL4 lymphoma models established in IFNAR-deficient mice while showing robust tumor control in wild-type mice, indicating the necessity for host type I IFN responsiveness to produce optimal radiation-mediated antitumor activity [86].